Compositions and methods for treating cognitive deficits
A method of treating or preventing cognitive impairment deficits in subjects with age-associated cognitive decline or a dementing illness includes administering to the subject a therapeutically effective amount of amylin, an amylin agonist, or an amylin derivative to treat the cognitive impairment or deficit.
1. A method of treating cognitive impairment or deficit associated with mild cognitive impairment or Alzheimer's disease of a subject in need thereof, comprising:
administering to the subject a therapeutically effective amount of amylin, an amylin agonist, or an amylin derivative to treat the cognitive impairment or deficit of the subject.
2. The method of claim 1 , wherein the amount of the amylin, amylin agonist, or amylin derivative administered to the subject is an amount effective to increase cognitive scores; improve memory; or slow the progression of dementia.
3. The method of claim 1 , further comprising administering a therapeutically effective amount of leptin.
4. The method of claim 1 , further comprising administering a therapeutically effective amount of an acetylcholinesterase inhibitor to the subject.
5. The method of claim 1 , wherein the subject has at least one condition selected from the group consisting of obesity, insulin resistance, diabetes, hypertension, and an apolipoprotein E4 genotype.
6. A method of treating cognitive impairment or deficit associated with mild cognitive impairment or Alzheimer's disease of a subject in need thereof, comprising:
administering to the subject a therapeutically effective amount of amylin, an amylin agonist, or an amylin derivative in combination with a therapeutically effective amount of leptin to treat the cognitive impairment or deficit of the subject.
7. The method of claim 6 , wherein the amount of the amylin, amylin agonist, or amylin derivative in combination with the leptin administered to the subject is an amount effective to increase cognitive scores; improve memory; or slow the progression of dementia.
8. The method of claim 6 , further comprising administering a therapeutically effective amount of an acetylcholineesterase inhibitor to the subject.
9. The method of claim 6 , wherein the subject has at least one condition selected from the group consisting of obesity, insulin resistance, diabetes, hypertension, and an apolipoprotein E4 genotype.
10. A method of treating cognitive impairment or deficit associated mild cognitive impairment or Alzheimer's disease in a subject in need thereof, comprising:
administering to the subject a therapeutically effective amount of amylin, an amylin agonist, or an amylin derivative in combination with a therapeutically effective amount of an acetylcholinesterase inhibitor to treat the cognitive impairment or deficit.
11. The method of claim 10 , wherein the amount of the amylin, amylin agonist, or amylin derivative in combination with the acetylcholinesterase inhibitor administered to the subject is an amount effective to increase cognitive scores; improve memory; or slow the progression of dementia of the affected subject.
12. The method of claim 10 , further comprising administering a therapeutically effective amount of leptin.
13. The method of claim 10 , wherein the subject has at least one condition selected from the group consisting of obesity, insulin resistance, diabetes, hypertension, and an apolipoprotein E4 genotype.